Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare (VMD) Chief Financial Officer Trae Fitzgerald reported a mix of equity awards vesting, tax withholding, and new grants. On January 17, 2026, 9,590 restricted stock units and 2,397 cash-settled phantom share units vested, each unit economically equal to one common share. To cover taxes from RSU vesting, 3,132 common shares were withheld at $7.33 per share, based on the January 16, 2026 closing price, and 2,397 common shares were delivered back to the company in connection with phantom share settlement. After these transactions, Fitzgerald directly held 89,452 common shares.
On January 19, 2026, Fitzgerald received new equity awards of 46,662 restricted stock units and 11,666 phantom share units, each with a stated value of $0 per unit on grant and scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.
Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity compensation transactions. On January 17, 2026, 4,884 restricted stock units and 1,221 cash-settled phantom share units vested, resulting in the acquisition of the same number of common shares. To cover tax obligations tied to the RSU vesting, 1,595 common shares were withheld at a per share value of $7.33, leaving 28,792 common shares held directly after the transactions.
On January 19, 2026, Trahan was granted 50,360 new restricted stock units and 12,590 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of their grant date. Each RSU represents a right to receive one common share, while each phantom share represents the cash value of one common share on the vesting date.
Viemed Healthcare, Inc. reported a Third Amendment to its Credit Agreement with Regions Bank and other lenders. The change extends the Borrower’s delayed draw term loan commitment expiration date to November 29, 2026, from November 29, 2025, with additional technical amendments. This keeps the facility available for an extra year under the amended terms.
The company also made an Investor Deck Presentation available and may use it in discussions with investors and analysts. As indicated, this presentation and related Item 7.01 information are furnished, not filed, under the Exchange Act.
Viemed Healthcare (VMD) reported Q3 results showing continued top-line growth alongside active capital deployment. Revenue reached $71.9 million, up from $58.0 million a year ago, driven by ventilator rentals and expanding equipment sales and services. Gross profit was $41.3 million versus $34.4 million. Net income attributable to the company was $3.5 million (diluted EPS $0.09) compared with $3.9 million (EPS $0.10) last year as operating costs rose with growth and integration.
Year-to-date, revenue totaled $194.1 million vs. $163.6 million, and diluted EPS was $0.23 vs. $0.17. Operating cash flow was strong at $33.5 million. The company closed the Lehan Drugs acquisition on July 1 for $28.7 million, adding goodwill of $25.5 million. Debt increased under the 2022 facilities to $21.1 million from $4.6 million at year-end, while cash ended the quarter at $11.1 million. Viemed repurchased 1,976,441 shares for $13.6 million under its 2025 program, reducing the quarter-end share count to 38,017,907. On October 29, the company repaid $5.0 million on its revolver.
Viemed Healthcare (VMD) furnished an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The company provided a press release and a Financial Supplement as exhibits.
The materials are furnished under Item 2.02 and, under General Instruction B.2, are not deemed filed or subject to Section 18 liabilities. Exhibits include the press release (99.1) and Financial Supplement (99.2), both dated November 5, 2025.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.
On 08/22/2025 Viemed Healthcare director and General Counsel Jeremy Trahan experienced equity award activity tied to prior grants. 2,986 cash-settled phantom share units vested and were reported as a cash settlement and simultaneous disposition of the underlying shares at a per-share value of $7.31. 5,971 Restricted Stock Units vested and converted into common shares, with 1,634 of those shares withheld to satisfy tax withholding. The reporting person holds 25,503 common shares following these transactions.
Kaushal Nitin, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and increases in beneficial ownership. The filing shows transactions on August 19–20, 2025 in which the reporting person acquired 15,732 common shares and received restricted stock unit grants totaling 34,518 RSUs across two grant dates. One RSU grant from August 20, 2024 vested August 20, 2025 and corresponds to 15,732 shares; a separate RSU grant on August 19, 2025 vests August 19, 2026 for 18,786 shares. Following the reported transactions, the filing lists 142,575 common shares as beneficially owned by the reporting person. The form is signed by an attorney-in-fact.
Timothy Smokoff, a director of Viemed Healthcare, Inc. (VMD), received equity awards in August 2025. The Form 4 shows grants and the resulting ownership changes: 15,732 restricted stock units (RSUs) were reported as acquired on 08/20/2025 and 15,029 RSUs plus 3,757 phantom share units were acquired on 08/19/2025. After the 08/20/2025 transaction the filing shows the reporting person beneficially owned 95,518 common shares. The RSUs granted vest on specified future dates, and each phantom share represents a right to receive the cash value of one common share at vesting.
Randy E. Dobbs, a director of Viemed Healthcare, Inc. (VMD), reported changes in his beneficial ownership of the issuer's common stock on transactions dated 08/19/2025 and 08/20/2025. The filing shows a grant and vesting activity: Restricted Stock Units (RSUs) and Phantom Share Units were granted on 08/19/2025 (16,763 RSUs and 4,191 phantom units) that vest on 08/19/2026, and RSUs granted on 08/20/2024 that vest on 08/20/2025 are referenced in the explanations.
The reported result of the 08/20/2025 activity is an acquisition entry of 17,784 common shares (code M) and a reported total of 125,490 shares beneficially owned following the reported transaction(s). The filing was signed by an attorney-in-fact on 08/20/2025.